According to Cognitive Market Research, the Global Radiotheranostics Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.

Based on Radioisotope Type, the Lutetium-177 segment will dominate the global Radiotheranostics market in the year 2023. Based on this Radioisotope type, the market is divided into iodine-131, iodine-12, gallium-68, lutetium-177, 18f with y-90 and others.
Based on Application, the Oncology segment dominated the global Radiotheranostics market. Based on Application, the global Radiotheranostics market is segmented into oncology and non-oncology
Based on the approach, the targeted therapeutic segment will dominate the global Radiotheranostics market in 2023. Based on the approach, the market is divided into targeted therapeutic and targeted diagnostic.
Based on End-users, the hospitals & clinics segments will dominate the global Radiotheranostics market in 2023. Based on these end-users, the market is divided into diagnostic centers, hospitals & clinics, and others.
The North American region accounted for the highest market share in the Global Radiotheranostics Market. 
Throughout the projection period, Europe is expected to increase at the fastest rate.

CURRENT SCENARIO OF THE RADIOTHERANOSTICS MARKET

Key factors driving the growth of the Radiotheranostics Market

The high prevalence of cancer is one of the factors driving the market for Radiotheranostics

The exponential growth of the global Radiotheranostics industry is driven by the increasing prevalence of cancer. The technology plays a significant role in the fight against cancer. It offers personalized medicine by using paired diagnostic and therapeutic radionuclide probes. These probes enable selective and targeted detection and the treatment of specific cells, especially cancer cells, specific to each patient's condition.

For instance, according to the Global Cancer Observatory data, over 19 million people across the globe suffered from cancer in 2020. The report also estimated that the risk of developing cancer before the age of 75 years was around 20.4%. (Source; https://pubmed.ncbi.nlm.nih.gov/33538338/)

According to the publication by the ASCO Post in June 2021, every year, there are around 50,000 new cases of cancer in Morocco, causing around 13.4% of deaths in the country. According to the same source, the most common type of tumor, regardless of gender, is breast cancer which accounts for 20% of cases while lung cancer (11.4%) is in the second place, followed by colon cancer (6.7%). (Source; https://ascopost.com/issues/june-25-2021/cancer-in-morocco-access-to-innovative-treatments-and-research-status/)

According to an article published by the National Centers for Biotechnology Information in July 2020, there is an increasing prevalence of ischemic heart disease across the globe, as it affects 1,655 per 100,000 individuals, which may rise up to 1,845 per 100,000 individuals by 2030. (Source; https://pubmed.ncbi.nlm.nih.gov/32742886/)

SPECT and PET are modern systems used to detect and treat cancer, cardiovascular diseases, and other neurology related diseases. PET installations across the world have cyclotrons beside a PET machine. PET radioisotopes have relatively short half-lives. Once the radioactive isotope is produced, it has to be synthesized and injected into a patient as soon as possible.

According to the American Nuclear Society, 90% of radioisotopes are used in gamma cameras or PET scan nuclear diagnostics. The remaining 10% are used in radioactive therapeutics drugs to treat diseases such as cancer, heart diseases, gastrointestinal, endocrine, and neurological disorders. (Source; https://world-nuclear.org/information-library/non-power-nuclear-applications/radioisotopes-research/radioisotopes-in-medicine.aspx)

The rising incidence of cancer is driving up demand for radiotheranostics in the healthcare industry, which is driving market expansion. Offering diagnostic and therapeutic skills, enabling accurate cancer cell imaging, and facilitating targeted therapy—which improves treatment outcomes and is another important growth-inducing factor—are critical to the management of cancer. In addition, the capacity of radiopharmaceuticals to precisely identify cancer aids in the selection of the best course of treatment for...

According to Cognitive Market Research, the Global Medical Cyclotron Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.

Based on Product Type, the 16-18 MeV segment will dominate the global Medical Cyclotron market in the year 2023. Based on this product type, the market is divided into 10-12 MeV, 16-18 MeV, 19 -24 MeV, and 24 MeV and above.
Based on Application, the Oncology segment dominated the global Medical Cyclotron market. Based on Application, the global Medical Cyclotron market is segmented into Oncology, neurology, cardiology, and other applications
Based on Type, the Fixed cyclotron segments will dominate the global Medical Cyclotron market in the year 2023. Based on this type, the market is divided into fixed and mobile segments.
Based on End-users, the hospital segments will dominate the global Medical Cyclotron market in the year 2023. Based on these end-users, the market is divided into Hospital, Specialized Clinics, Pharmaceutical Companies
The North American region accounted for the highest market share in the Global Medical Cyclotron Market. 
Over the course of the projection period, Europe is expected to increase at the fastest rate.

CURRENT SCENARIO OF THE MEDICAL CYCLOTRON MARKET

Key factors driving the growth of the Medical Cyclotron Market

The high prevalence of cancer is one of the factors driving the market for Medical Cyclotron

For instance, according to the Global Cancer Observatory data, over 19 million people across the globe suffered from cancer in 2020. The report also estimated that the risk of developing cancer before the age of 75 years was around 20.4%. (Source; https://pubmed.ncbi.nlm.nih.gov/33538338/)

According to the publication by the ASCO Post in June 2021, every year, there are around 50,000 new cases of cancer in Morocco, causing around 13.4% of deaths in the country. According to the same source, the most common type of tumor, regardless of gender, is breast cancer which accounts for 20% of cases while lung cancer (11.4%) is in the second place, followed by colon cancer (6.7%). (Source; https://ascopost.com/issues/june-25-2021/cancer-in-morocco-access-to-innovative-treatments-and-research-status/)

According to an article published by the National Centers for Biotechnology Information in July 2020, there is an increasing prevalence of ischemic heart disease across the globe, as it affects 1,655 per 100,000 individuals, which may rise up to 1,845 per 100,000 individuals by 2030. (Source; https://pubmed.ncbi.nlm.nih.gov/32742886/)

SPECT and PET are modern systems used to detect and treat cancer, cardiovascular diseases, and other neurology related diseases. PET installations across the world have cyclotrons beside a PET machine. PET radioisotopes have relatively short half-lives. Once the radioactive isotope is produced, it has to be synthesized and injected into a patient as soon as possible.

According to the American Nuclear Society, 90% of radioisotopes are used in gamma cameras or PET scan nuclear diagnostics. Remaining 10% are used in radioactive therapeutics drugs to treat diseases such as cancer, heart diseases, gastrointestinal, endocrine, and neurological disorders. (Source; https://world-nuclear.org/information-library/non-power-nuclear-applications/radioisotopes-research/radioisotopes-in-medicine.aspx)

Molecular imaging with novel radiopharmaceuticals has been engineered to target specific subcellular processes and improve diagnostic accuracy using radioactive molecule as a tracer. These factors are expected to bolster the global medical cyclotron market in the next few years.

Rise in awareness about efficient utilization of radiopharmaceuticals stimulating growth for the market

With less harmful side effects, radionuclide therapy has become an effective treatment option for chronic illnesses. Consequently, there has been a significant increase in the manufacture of radioisotopes worldwide for use in nuclear medicine and medical imaging.

The World Nuclear Association reports that radioisotopes find applications in medical practices across more than 10,000 hospitals worldwide. Around 90% of medical procedures, including diagnosis and treatment of conditions such as infectious diseases, cancer, and neurological disorders, rely on these radioisotopes. (So...

BackgroundIron deficiency anemia (IDA) is a prevalent hematological complication associated with gastrointestinal (GI) cancers due to an increased loss of iron and decreased iron absorption. The purpose of this systematic review is to evaluate the use of parenteral iron to treat IDA in patients with GI cancer.MethodsPubMed, Cochrane, EMBASE, CINHAL and Scopus were searched from January 1, 2010 to September 29, 2023 with no language restrictions. We excluded editorials, case reports, abstracts, conference papers, and poster presentations. Studies were included if they discussed IDA, GI neoplasms, use of iron supplementation (with or without erythropoietin-stimulating agents [ESAs]), defined anemia and had an adult patient population. We assessed the efficacy of parenteral iron in comparison to other iron supplementation methods when treating IDA in patients with GI cancer. The Cochrane Risk of Bias Tool 2 (RoB 2) and the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) assessment tools were used to assess the quality of the included studies. Moreover, the Cochrane Effective Practice and Organization data collection form was used to collect pertinent study information.ResultsOur search yielded 3,969 studies across all databases. Twenty-one studies were included (6 randomized control trials; 15 non-randomized studies). Of the 15 studies evaluating hemoglobin (Hb) response, seven studies found an increase in Hb levels when patients were treated with IV iron. The 14 studies evaluating red blood cell (RBC) transfusion rates found conflicting differences in RBC transfusion needs when treated with IV iron. Studies analyzing health related outcomes typically found an increase in quality of life and decreased post-operative complications.DiscussionThis review demonstrates improved outcomes of IDA in patients with GI cancer treated with IV iron instead of other iron supplementation methods. Timely diagnosis and appropriate IDA management can greatly improve quality of life in this patient population, especially if myelosuppressive chemotherapy is required.